Overexpression of both Trx and TrxR has been reported in triple-negative breast cancer patients with a poor outcome, while increased Trx expression correlates with aggressive tumors, poor clinical prognosis, and lower patient survival rates in non-small cell lung carcinoma (NSCLC) and colorectal carcinoma (Kakolyris et al., 2001; Raffel et al., 2003; Yoo et al., 2006; Raninga et al., 2020). The gene discussed is TXN; the disease is triple-negative breast carcinoma.